Pure Global

Comparison Between Low FODMAP and SSRD in IBS - Trial NCT05192603

Access comprehensive clinical trial information for NCT05192603 through Pure Global AI's free database. This phase not specified trial is sponsored by Region Skane and is currently Enrolling by invitation. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05192603
Enrolling by invitation
dietary supplement
Trial Details
ClinicalTrials.gov • NCT05192603
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Comparison Between Low FODMAP and SSRD in IBS
Comparison in the Effects and Mechanisms Between Low Fermentable-, Oligo-, di-, and Monosaccharides and Polyols (FODMAP) and Starch- and Sucrose-reduced Diet (SSRD) in Irritable Bowel Syndrome (IBS)

Study Focus

low FODMAP or SSRD

Interventional

dietary supplement

Sponsor & Location

Region Skane

Malmö, Sweden

Timeline & Enrollment

N/A

Mar 01, 2022

Mar 31, 2029

200 participants

Primary Outcome

Efficiency on bowel and extra-intestinal symptoms,Efficiency on bowel and extra-intestinal symptoms,Efficiency on bowel symptoms,Efficiency on bowel symptoms

Summary

The aim of the present study is to compare the efficiency of low FODMAP and SSRD to reduce
 symptoms in IBS, and to study the mechanisms and consequences of the two diets.

ICD-10 Classifications

Irritable bowel syndrome with predominant constipation [IBS-C]
Irritable bowel syndrome
Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Irritable bowel syndrome with mixed bowel habits [IBS-M]
Other and unspecified irritable bowel syndrome

Data Source

ClinicalTrials.gov

NCT05192603

Non-Device Trial